Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Effect of Tetrabenazine on Stroop Interference in HD

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2017 by New York Medical College
Information provided by (Responsible Party):
Robert Fekete, New York Medical College Identifier:
First received: April 15, 2013
Last updated: March 27, 2017
Last verified: March 2017
Tetrabenazine has been shown to improve gating of abnormal visual stimuli and improve postural stability in Huntington disease (HD) patients as measured by computerized dynamic posturography testing. This study aims to elucidate whether partial dopaminergic depletion via low dose tetrabenazine has a similar effect on masking out of abnormal visual stimuli on the Stroop interference test.

Condition Intervention Phase
Huntington Disease
Drug: Tetrabenazine withdrawal
Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: Effect of Tetrabenazine on Stroop Interference in Huntington Disease

Resource links provided by NLM:

Further study details as provided by New York Medical College:

Primary Outcome Measures:
  • Change in Stroop Interference Score [ Time Frame: 6 hours ]
    Participants will have Stroop Visual Interference Scores measured while OFF tetrabenazine for at least 3 days. Two doses of 12.5 mg tetrabenazine will be subsequently administered: first dose just after the Stroop test and second dose 3 hours later. Stroop Visual Interference Scores will be measured again in the ON state, 6 hours after the initial OFF measurement.

Estimated Enrollment: 10
Study Start Date: March 2013
Estimated Study Completion Date: January 1, 2018
Estimated Primary Completion Date: January 1, 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Tetrabenazine withdrawal
Tetrabenazine will be withdrawn for at least 3 days in Huntington disease patients currently taking the medication.
Drug: Tetrabenazine withdrawal
Tetrabenazine will be withdrawn for at least 3 days in Huntington disease patients currently on the drug. Patients will be examined via Stroop test in the OFF state. Two doses of 12.5 mg tetrabenazine will be introduced, spaced 3 hours apart. Stroop test will be performed 6 hours after initial OFF Stroop test.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Established diagnosis of Huntington disease by movement disorders expert
  • Patients currently taking tetrabenazine.
  • Patients should not have taken dopamine receptor blocking medication for at least three days

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01834911

Contact: Robert Fekete, MD 9145944293
Contact: Robert Fekete, MD 9143451313

United States, New York
Terence Cardinal Cooke Health Care Center Recruiting
New York, New York, United States, 10029
Contact: Katherine Becker, LMSW    212-360-3711      
Principal Investigator: Robert Fekete, MD         
Sub-Investigator: Silky Singh, MD         
Sponsors and Collaborators
New York Medical College
  More Information

Responsible Party: Robert Fekete, Principal Investigator, New York Medical College Identifier: NCT01834911     History of Changes
Other Study ID Numbers: L-10,830
Study First Received: April 15, 2013
Last Updated: March 27, 2017

Keywords provided by New York Medical College:
Huntington disease

Additional relevant MeSH terms:
Huntington Disease
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Genetic Diseases, Inborn
Cognition Disorders
Neurocognitive Disorders
Mental Disorders
Adrenergic Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs processed this record on May 25, 2017